Week in Review: Kumquat Signs $2 Billion US-China Deal with Lilly for Novel Immune Drugs

Deals and Financings   San Diego 's Kumquat Biosciences formed a $2 billion partnership with Lilly to discover small molecule tumor-specific immunoncology drugs; Kumquat will retain China rights to the drugs; Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Hong Kong IPO to support clinical trials of two siRNA therapeutics; MicroPort Cardiac Rhythm Management closed a $150 million Series C financing for its implantable pacemaker and defibrillator devices; Bota Bio, a San Francisco-Hangzhou industrial synthetic biotech company, raised $100 million in a B round for bio-manufacturing of common household and pharma products; Zion Pharma of Hong Kong raised $40 million to advance its small molecule cancer drugs, including a HER2 inhibitor aimed at treating brain metastases; Neukio Biotherapeutics, a  Shanghai  startup, completed a $40 million Angel round to develop universal CAR-T therapies; Guangzhou Lupeng Pharma closed a $35 million pre-B financing for global clinical trials of its novel selective Bcl-2 inhibitor for lymphoma indications;   I-Mab, a  Shanghai  biotech, announced plans to add a listing on the STAR Board of the Shanghai Exchange following a 2020 NASDAQ debut;  Trials and Approvals   Shanghai Zai Lab and  Boston 's Entasis Therapeutics have completed enrollment in a global Phase III trial of a novel combination antibacterial; Suzhou Innovent Bio started a China Phase I trial of an anti-PD-1/TIGIT bi-specific antibody in malignant tumors, especially GI cancers; Shanghai 's I-Mab will start a US Phase I trial of its novel nasally delivered immunotherapy for Alzheimer's disease.  Stock Symbols: (NSDQ: IMAB) (NSDQ: ZLAB; HKEX: 9688) (NSDQ: ETTX) (HK: 01801) Share this with colleagues: // //